-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $44

Benzinga·05/22/2026 11:59:15
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target from $40 to $44.